Cemiplimab vs Pembrolizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Cemiplimab
Marketed by Regeneron Pharmaceuticals and partners
NCT03088540 · Phase 3 · completed
This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.
Next expected readout: December 2026 · NCT06623656 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)
Result source: NCT03088540
Pembrolizumab
Marketed by Merck & Co.
NCT02142738 · Phase 3 · completed
The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).
Next expected readout: November 2026 · NCT06545331 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)
Result source: NCT02142738
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cemiplimab | Pembrolizumab |
|---|---|---|
| PFS, median | 6.3 vs 5.3vs ChemotherapyNCT030885403 other results
| 8.8 vs 4.9+3.9 vs placeboNCT0257868017 other results
|
| OS, median | 21.1 vs 12.9+8.2 vs placeboNCT034096143 other results
| 15.9 vs 11.3+4.6 vs placeboNCT0277543515 other results
|
| ORR | 43.6% vs 22.1%+21.5 vs placeboNCT034096143 other results
| 47.6% vs 18.9%+28.7 vs placeboNCT0257868014 other results
|
| Duration of response, median | 16.4 vs 7.3+9.1 vs placeboNCT034096143 other results
| 11.2 vs 7.8+3.4 vs placeboNCT025786808 other results
|
PFS, median
- Cemiplimab
- 6.3 vs 5.3vs ChemotherapyNCT03088540
3 other results
- 8.2 vs 5.5 NCT03409614
- 6.5 vs 6.4 NCT03409614
- 6.4 vs 6.4 NCT03409614
- Pembrolizumab
- 8.8 vs 4.9+3.9 vs placeboNCT02578680
17 other results
- 6.4 vs 4.8 NCT02775435
- 5.6 vs 5.5 NCT03515837
- 5.6 vs 4.2 NCT03976375
- 4 vs 2.5 NCT02864394
- 3.3 vs 3 NCT02864394
- 7.1 NCT03976323
- 8.3 NCT03976323
- 6.5 vs 6.4 NCT02220894
- 6.2 vs 6.7 NCT02220894
- 5.4 vs 6.6 NCT02220894
- 2.5 vs 2.4 NCT04165096
- 4.5 vs 5.2 NCT03971474
- 29 NCT03631784
- 45.3 NCT03631784
- 7 NCT05077709
- 2.6 NCT02955758
- 4.4 NCT02733159
OS, median
- Cemiplimab
- 21.1 vs 12.9+8.2 vs placeboNCT03409614
3 other results
- 23.4 vs 13.7 NCT03088540
- 15.9 vs 13.9 NCT03409614
- 20.1 vs 13.9 NCT03409614
- Pembrolizumab
- 15.9 vs 11.3+4.6 vs placeboNCT02775435
15 other results
- 15.9 vs 14.7 NCT03515837
- 20 vs 12.2 NCT02220894
- 18 vs 13 NCT02220894
- 16.4 vs 12.1 NCT02220894
- 11.3 vs 12 NCT03976375
- 12.3 vs 10.9 NCT02864394
- 12.9 vs 10.6 NCT02864394
- 20.7 NCT03976323
- 23 NCT03976323
- 14.5 vs 11.6 NCT03971474
- 35.6 NCT03631784
- 56.7 NCT03631784
- 9.8 NCT02733159
- 22.3 NCT05077709
- 13.3 NCT02955758
ORR
- Cemiplimab
- 43.6% vs 22.1%+21.5 vs placeboNCT03409614
3 other results
- 42.3% vs 21.4% NCT03088540
- 40.7% vs 28.3% NCT03409614
- 36.7% vs 28.3% NCT03409614
- Pembrolizumab
- 47.6% vs 18.9%+28.7 vs placeboNCT02578680
14 other results
- 57.9% vs 38.4% NCT02775435
- 29% vs 27.1% NCT03515837
- 39.1% vs 32% NCT02220894
- 33.2% vs 28.9% NCT02220894
- 27.2% vs 26.5% NCT02220894
- 44.8% vs 27.8% NCT02142738
- 22.7% vs 14.3% NCT03976375
- 22.7% vs 12.5% NCT03976375
- 28.1% vs 7.1% NCT02864394
- 20.7% vs 5.7% NCT02864394
- 5.4% vs 11.1% NCT04165096
- 71.4% NCT03631784
- 75.5% NCT03631784
- 22% vs 28% NCT03971474
Duration of response, median
- Cemiplimab
- 16.4 vs 7.3+9.1 vs placeboNCT03409614
3 other results
- 24.1 vs 5.9 NCT03088540
- 7.8 vs 6.2 NCT03409614
- 15.9 vs 6.2 NCT03409614
- Pembrolizumab
- 11.2 vs 7.8+3.4 vs placeboNCT02578680
8 other results
- 7.7 vs 4.8 NCT02775435
- 6.3 vs 5.6 NCT03515837
- 6.9 vs 6.8 NCT03976375
- 16.6 vs 6.4 NCT02864394
- 16.6 vs 6.3 NCT02864394
- 12.9 vs 5.6 NCT03971474
- 14.6 NCT02733159
- 12.5 NCT05077709
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cemiplimab: 4 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cemiplimab | Pembrolizumab Rows use multiple source trials |
|---|---|---|
| Dropout rate | 79%Cemiplimaba NCT03088540 · Phase 3 show 10 more results—Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 90.7%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 90.1%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 0%30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 0%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | n/a: no completion milestonePembrolizumabb NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results—Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 54%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 58.8%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination n/a: no completion milestone NCT02775435 · Phase 3 · combination n/a: no completion milestone NCT02220894 · Phase 3 n/a: no completion milestone NCT02504372 · Phase 3 89.3%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence —Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination 33%Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination 0%Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination 0%Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence —Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03515837 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03875092 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03950674 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02864394 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT03850444 · Phase 3 · registry result, not featured evidence 2.5% NCT03634241 · Phase 2 · registry result, not featured evidence 90.5%Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 60%Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT04165096 · Phase 2 · registry result, not featured evidence · combination 0%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 50%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 80.7%1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 89.2%2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 94.4%2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 0% NCT02955758 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 3.2% NCT02733159 · Phase 2 · registry result, not featured evidence 87.7% NCT03004183 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT03971474 · Phase 2 · registry result, not featured evidence · combination 86.4% NCT03087760 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.3%Cemiplimaba NCT03088540 · Phase 3 show 10 more results—Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 0%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 0%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 0.3%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination —30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination —10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | 8.4%Pembrolizumabb NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results—Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 4.9%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 6.7%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 11.5% NCT02775435 · Phase 3 · combination 19.9% NCT02220894 · Phase 3 — NCT02504372 · Phase 3 —200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence —Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination —Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence —Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination — NCT03515837 · Phase 3 · registry result, not featured evidence · combination 3.1% NCT03875092 · Phase 3 · registry result, not featured evidence · combination — NCT03950674 · Phase 3 · registry result, not featured evidence · combination — NCT02864394 · Phase 3 · registry result, not featured evidence 12.5% NCT03850444 · Phase 3 · registry result, not featured evidence — NCT03634241 · Phase 2 · registry result, not featured evidence —Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination —Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination —800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination — NCT04165096 · Phase 2 · registry result, not featured evidence · combination —Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence —Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence —1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination —2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination —2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination — NCT02955758 · Phase 2 · registry result, not featured evidence —Pembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02733159 · Phase 2 · registry result, not featured evidence 12.3% NCT03004183 · Phase 2 · registry result, not featured evidence 11.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination — NCT03087760 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 36.8%Cemiplimaba NCT03088540 · Phase 3 show 10 more results27.1%Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 35.2%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 30.4%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 33.3%30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 40%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 23.8%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 11.1%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 25%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 60%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | —Pembrolizumabb NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results51.3%Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 16.7%Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 38.8%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 36.6%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 57.5%Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 22.2%Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 46% NCT02775435 · Phase 3 · combination 41% NCT02220894 · Phase 3 24.5% NCT02504372 · Phase 3 20.7%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence 35%Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination 37.7%Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination 0%Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination 7.7%Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination 23.4%Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination 50%Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination 100%Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence 54.7%Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination 35.1% NCT03515837 · Phase 3 · registry result, not featured evidence · combination 53.8% NCT03875092 · Phase 3 · registry result, not featured evidence · combination 36% NCT03950674 · Phase 3 · registry result, not featured evidence · combination 36.2% NCT02864394 · Phase 3 · registry result, not featured evidence 32.8% NCT03850444 · Phase 3 · registry result, not featured evidence 7.5% NCT03634241 · Phase 2 · registry result, not featured evidence 9.5%Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 20%Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 60.8%800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination 46.7%200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination 52.5%Pembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination 47.6%Pembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination 37.8% NCT04165096 · Phase 2 · registry result, not featured evidence · combination 10.8%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 20%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 47.4%1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 54.1%2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 25%2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 36% NCT02955758 · Phase 2 · registry result, not featured evidence 58.9%Pembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination 45.1%Pembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 85% NCT02733159 · Phase 2 · registry result, not featured evidence 51.8% NCT03004183 · Phase 2 · registry result, not featured evidence 40.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination 45.5% NCT03087760 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 10 more resultsanaemia 48.1% (placebo 39.9%) neutropenia 28.7% (placebo 12.4%) alopecia 27.8% (placebo 43.8%) NCT03409614 · Phase 3 · combination anaemia 33.9% (placebo 39.9%) nausea 28.4% (placebo 16.3%) fatigue 21.1% (placebo 8.5%) NCT03409614 · Phase 3 · combination anaemia 44.2% (placebo 39.9%) alopecia 37.5% (placebo 43.8%) nausea 25.3% (placebo 16.3%) NCT03409614 · Phase 3 · combination 30 mg/kg infusion related reaction 66.7% anaemia 33.3% abdominal pain 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg infusion related reaction 66.7% anaemia 40% constipation 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg in combination with cemiplimab infusion related reaction 42.9% cough 33.3% fatigue 33.3% NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 10 mg/kg infusion related reaction 55.6% fatigue 33.3% dehydration 22.2% NCT05259696 · Phase 1/2 · registry result, not featured evidence 3 mg/kg abdominal pain 25% arthralgia 25% back pain 25% NCT05259696 · Phase 1/2 · registry result, not featured evidence 1 mg/kg abdominal pain 60% nausea 60% vomiting 40% NCT05259696 · Phase 1/2 · registry result, not featured evidence | b diarrhoea 26.6% dyspnoea 26.6% fatigue 24% NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 42 more resultsupper respiratory tract infection 33.3% constipation 16.7% decreased appetite 16.7% NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 10 mg/kg fatigue 25.7% decreased appetite 23.3% dyspnoea 23% NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 2 mg/kg decreased appetite 30.7% fatigue 30.1% nausea 25.7% NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 nausea 57.3% (placebo 51%) anaemia 45.9% (placebo 45%) fatigue 42.7% (placebo 39.6%) NCT02578680 · Phase 3 · combination abdominal pain 22.2% (placebo 6.4%) cough 22.2% (placebo 30.7%) diarrhoea 22.2% (placebo 20.3%) NCT02578680 · Phase 3 · combination anaemia 53.2% (placebo 49.6%) alopecia 46% (placebo 37.5%) nausea 36.3% (placebo 32.1%) NCT02775435 · Phase 3 · combination weight increased 22.8% (placebo 28.9%) pruritus 21.6% (placebo 12.7%) hypothyroidism 20.7% (placebo 4.6%) NCT02504372 · Phase 3 200 mg IV Q3W hypothyroidism 17.3% anaemia 12.7% constipation 11.3% NCT03715205 · Phase 4 · registry result, not featured evidence anaemia 36.2% nausea 24% fatigue 17.2% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 37.7% nausea 19% aspartate aminotransferase increased 16.6% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 14.3% covid-19 14.3% headache 14.3% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 15.4% cough 15.4% productive cough 15.4% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 38.4% nausea 30.9% neutropenia 23.4% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anemia 75% cough 75% abdominal pain 50% NCT03867175 · Phase 3 · registry result, not featured evidence · combination alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03867175 · Phase 3 · registry result, not featured evidence hypertension 41.4% diarrhoea 40.9% hypothyroidism 35.4% NCT03976375 · Phase 3 · registry result, not featured evidence · combination anaemia 40.4% (placebo 44.7%) nausea 39.2% (placebo 43.5%) neutrophil count decreased 36.7% (placebo 45.9%) NCT03515837 · Phase 3 · registry result, not featured evidence · combination alopecia 78.5% white blood cell count decreased 78.5% neutrophil count decreased 76.9% NCT03875092 · Phase 3 · registry result, not featured evidence · combination nausea 72% (placebo 53.3%) constipation 64% (placebo 73.3%) decreased appetite 56% (placebo 60%) NCT03950674 · Phase 3 · registry result, not featured evidence · combination anaemia 33.3% aspartate aminotransferase increased 21.6% cough 21.6% NCT02864394 · Phase 3 · registry result, not featured evidence fatigue 45% investigations 25% alanine aminotransferase increased 20% NCT03634241 · Phase 2 · registry result, not featured evidence anaemia 42.9% diarrhoea 33.3% fatigue 28.6% NCT05077709 · Phase 2 · registry result, not featured evidence · combination asthenia 40% blood creatinine increased 40% blood urea increased 40% NCT05077709 · Phase 2 · registry result, not featured evidence · combination 800 mg diarrhoea 29.4% fatigue 21.6% alanine aminotransferase increased 19.6% NCT03516981 · Phase 2 · registry result, not featured evidence · combination 200 mg pyrexia 23.3% constipation 20% decreased appetite 20% NCT03516981 · Phase 2 · registry result, not featured evidence · combination hypertension 52.5% diarrhoea 45% hypothyroidism 36.3% NCT03516981 · Phase 2 · registry result, not featured evidence · combination pruritus 29.3% cough 22% fatigue 20.7% NCT03516981 · Phase 2 · registry result, not featured evidence · combination fatigue 29.7% pruritus 29.7% nausea 24.3% NCT04165096 · Phase 2 · registry result, not featured evidence · combination anorexia 40% gastrointestinal disorders - other, specify 40% hypertension 40% NCT02681549 · Phase 2 · registry result, not featured evidence asthenia 34.2% dyspnoea 34.2% cough 29.8% NCT03625323 · Phase 2 · registry result, not featured evidence · combination asthenia 21.6% anaemia 18.9% cough 18.9% NCT03625323 · Phase 2 · registry result, not featured evidence · combination decreased appetite 36.1% dyspnoea 36.1% cough 30.6% NCT03625323 · Phase 2 · registry result, not featured evidence · combination nausea 24% decreased appetite 20% worsening abdominal pain 20% NCT02955758 · Phase 2 · registry result, not featured evidence anaemia 39.3% fatigue 34.8% alopecia 31.3% NCT03631784 · Phase 2 · registry result, not featured evidence · combination nausea 52% asthenia 40.2% anaemia 32.4% NCT03631784 · Phase 2 · registry result, not featured evidence · combination fatigue 21.4% nausea 12.5% back pain 10.7% NCT03004183 · Phase 2 · registry result, not featured evidence fatigue 56.5% hypoalbuminemia 44.9% hyponatremia 39.1% NCT03971474 · Phase 2 · registry result, not featured evidence · combination esophagitis 36.4% fatigue 36.4% hypothyroidism 22.7% NCT03087760 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 42 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cemiplimab
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
+ 36 further endpoints in the CSV export.
Pembrolizumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 7 more results
show 8 more results
show 1 more result
show 1 more result
show 3 more results
+ 44 further endpoints in the CSV export.
Melanoma
Shared mechanism: PD-1 · full Melanoma pipeline
Cemiplimab
Marketed by Regeneron Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT05608291 (registry estimate)
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT01866319 · Phase 3 · completed
The trial randomized 834 participants to two pembrolizumab schedules or active-control ipilimumab, with progression assessed by blinded independent radiology review and statistically significant improvements in progression-free survival and overall survival for both pembrolizumab schedules versus ipilimumab. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the objective clinical endpoints and favorable results.
Next expected readout: December 2026 · NCT02644369 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Melanoma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Cemiplimab: 3 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cemiplimab | Pembrolizumab |
|---|---|---|
| Dropout rate | 0%30 mg/kga NCT05259696 · Phase 1/2 · registry result, not featured evidence show 5 more results0%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 0%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | 89.3%200 mg IV Q3Wa NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results0%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 50%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 0%30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 0%27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 0%18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 57.1%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 92.3%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 92.5%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 91.6%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 93.2%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 100%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 100%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 89%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 90.2%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 100%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 100%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 100%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —30 mg/kga NCT05259696 · Phase 1/2 · registry result, not featured evidence show 5 more results—20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination —10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | —200 mg IV Q3Wa NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results—Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence —Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination —30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination —27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination —18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination —20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 12%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 15.3%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10.3%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 16.9%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 16.7%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 66.7%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 9.1%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 11.5%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 25%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 25%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 33.3%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 33.3%30 mg/kga NCT05259696 · Phase 1/2 · registry result, not featured evidence show 5 more results40%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 23.8%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 11.1%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 25%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 60%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | 20.7%200 mg IV Q3Wa NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results10.8%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 20%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 22.2%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 57.1%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 55.6%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 43.4%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45.3%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 36.8%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 20%Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 33.3%30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 41.7%27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 14.3%18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 14.3%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 43.9%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 41.2%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 42.6%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 41.5%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 30%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 33.3%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 42.6%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 55.7%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 25%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 0%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 33.3%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 30 mg/kga infusion related reaction 66.7% anaemia 33.3% abdominal pain 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence show 5 more results20 mg/kg infusion related reaction 66.7% anaemia 40% constipation 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg in combination with cemiplimab infusion related reaction 42.9% cough 33.3% fatigue 33.3% NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 10 mg/kg infusion related reaction 55.6% fatigue 33.3% dehydration 22.2% NCT05259696 · Phase 1/2 · registry result, not featured evidence 3 mg/kg abdominal pain 25% arthralgia 25% back pain 25% NCT05259696 · Phase 1/2 · registry result, not featured evidence 1 mg/kg abdominal pain 60% nausea 60% vomiting 40% NCT05259696 · Phase 1/2 · registry result, not featured evidence | 200 mg IV Q3Wa hypothyroidism 17.3% anaemia 12.7% constipation 11.3% NCT03715205 · Phase 4 · registry result, not featured evidence show 56 more resultsanorexia 40% gastrointestinal disorders - other, specify 40% hypertension 40% NCT02681549 · Phase 2 · registry result, not featured evidence 5 mg weekly fatigue 66.7% decreased appetite 55.6% cough 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 85.7% cough 42.9% hypophosphataemia 42.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 77.8% musculoskeletal and connective tissue disorders 55.6% cough 38.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 47.4% musculoskeletal and connective tissue disorders 44.7% decreased appetite 35.5% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly nausea 56.6% fatigue 54.7% musculoskeletal and connective tissue disorders 45.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 57.9% musculoskeletal and connective tissue disorders 44.7% blood alkaline phosphatase increased 36.8% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 3 mg weekly decreased appetite 50% cough 33.3% diarrhoea 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination dyspnea 90% fatigue 90% pain 70% NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination fatigue 100% cough 80% pain 60% NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 30 Gy over 5 fractions headache 33.3% agitation 16.7% dermatitis, other 16.7% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 27 Gy over 3 fractions symptomatic radionecrosis 16.7% constipation 8.3% dermatitis, other 8.3% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 18-21 Gy in one fraction symptomatic radionecrosis 14.3% agitation 0% constipation 0% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 20 mg/kg hypertension 28.6% anemia 14.3% arthralgia 14.3% NCT03236935 · Phase 1 · registry result, not featured evidence 10 mg/kg Q2W fatigue 58.9% diarrhoea 38.9% nausea 38.3% NCT01295827 · Phase 1 · registry result, not featured evidence 10 mg/kg Q3W fatigue 52.1% diarrhoea 35.5% nausea 34.5% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10 mg/kg Q2W fatigue 38.6% decreased appetite 27.2% dyspnoea 25.7% NCT01295827 · Phase 1 · registry result, not featured evidence 10 mg/kg Q3W fatigue 42.5% decreased appetite 30.7% cough 30% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10 mg/kg Q2W fatigue 50% decreased appetite 30% constipation 20% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 3 mg/kg Q2W back pain 66.7% nausea 66.7% breast pain 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence 2 mg/kg Q3W fatigue 47.5% nausea 34.6% diarrhoea 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 2 mg/kg Q3W fatigue 27.9% diarrhoea 19.7% constipation 16.4% NCT01295827 · Phase 1 · registry result, not featured evidence 1 mg/kg Q2W pruritus 75% abdominal pain upper 25% anaemia 25% NCT01295827 · Phase 1 · registry result, not featured evidence bradycardia 25% diarrhoea 25% fatigue 25% NCT01295827 · Phase 1 · registry result, not featured evidence diarrhoea 66.7% fatigue 66.7% pruritus 66.7% NCT01295827 · Phase 1 · registry result, not featured evidence decreased appetite 66.7% fatigue 50% depression 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 16 more results
show 7 more results
show 7 more results
show 19 more results
show 12 more results
show 18 more results
show 6 more results
show 1 more result
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Pembrolizumab's landscape